Lumena Pharmaceuticals
San Diego · Founded 2011
About Lumena Pharmaceuticals
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.
Company Facts
- Founded: 2011
- Legal name: Lumena Pharmaceuticals, Inc
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 5,001 – 10,000
- Estimated revenue: $10K – $50K
- Total funding: $70.6M
- Funding stage: M&A
- Last round: Series B (Mar 2014)
- Website: lumenapharma.com
- Phone: 617-380-7680
Social Profiles
Canonical: https://fsome.com/organization/lumena-pharmaceuticals-8381193 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.